



Regulated information

12 July 2010

NIH extends agreement with Galapagos until end 2012

Mechelen, Belgium; 12 July 2010 – Galapagos NV (Euronext: GLPG) announced today that the U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos' service division BioFocus for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. According to the terms of this agreement, Galapagos will be eligible to receive up to \$8.6 million (€7.0 million) over the course of the two year extension.

BioFocus runs a compound management facility for a number of industrial and U.S. government customers out of its Compound Focus, Inc. subsidiary in South San Francisco. Home to the MLSMR since 2004, this facility acquires and stores compounds under the NIH contract and distributes these compounds for high-throughput biological screening throughout the NIH's academic network in the U.S.

"We are pleased that the NIH has exercised its option to extend its long-standing collaboration with BioFocus' compound management facility for another two years. BioFocus has proven that it consistently delivers a high-quality service across the vast NIH screening center network," said Onno van de Stolpe, CEO of Galapagos.

About the Molecular Libraries Small Molecule Repository (a Roadmap initiative)

The NIH MLSMR collects samples for high throughput biological screening and distributes them to the NIH Molecular Libraries Screening Center Network. MLSMR is a key component of the Molecular Libraries Initiative, a NIH Roadmap project supporting '*new pathways to discovery in the 21st century*'. The project is funded in whole with U.S. federal funds from the National Institutes of Health, Department of Health and Human Services, under contract HHS-N-278-2004-41001C with Compound Focus, Inc.

About BioFocus

[BioFocus](http://www.biofocus.com) aims to expand its partners' drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, *in vitro* and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 250 employees based in the UK, the US and Switzerland. More info at: www.biofocus.com

About Galapagos

[Galapagos](http://www.galpagos.com) (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with four clinical and over 50 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to receive €3.3 billion in downstream milestones, plus royalties. Together with its BioFocus and Argenta service operations, Galapagos has over 670 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.galpagos.com

The logo for Galapagos, featuring the word "Galapagos" in a green, sans-serif font.The logo for BioFocus, featuring the word "BioFocus" in a green, sans-serif font. Below it, in a smaller font, is "A Galapagos Company". To the right of the text is a large, stylized orange bracket shape.

CONTACT

Galapagos NV

Onno van de Stolpe, CEO

Tel: +31 6 2909 8028

ir@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.